Company Management and Scientific Experts in Cardiac Cell Therapy and Immuno-Oncology to Discuss Science and Portfolio Drug Candidates
Mont-Saint-Guibert, Belgium – Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of cell therapies, will host an Investor & Analyst Day on Friday 30th January 2015 in New York City.
The event will bring together scientific experts and key opinion leaders in cardiology and immunooncology from the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine (MD, USA), the Institute of Cancer Sciences, University of Manchester (UK), the Mayo Clinic (MN, USA), Dartmouth College (NH, USA) and the Dana-Farber Cancer Institute (MA, USA). Together with members of Cardio3 BioSciences’ management team, they will provide a comprehensive overview of the company’s current pipeline in cardiac cell therapy, cardiac medical devices and immunooncology, substantiated with pre-clinical and clinical data
The objective of this event is to present the Company’s current pipeline of products, development perspectives for the coming years, and near and long-term business strategy. This event will also enable members of the financial community to meet with Cardio3 BioSciences’ management and key opinion leaders for in-depth discussion and understanding of the Company and its strategy.
Details of the Investor & Analyst Day:
- Date: Friday January 30, 2015
- Time: 7:30 AM – 12:15 PM ET
- Location: The New York Palace, 455 Madison Avenue, New York
Attendance at The Cardio3 BioSciences Analyst Day is by invitation only.
To request an invitation for the event, please contact Courtney Dugan or Taylor Donovan of The Ruth Group at cdugan@theruthgroup.com / tdonovan@theruthgroup.com or +1 646-536-7024 / 7017.
